Blood Tumor Mutational Burden as a Predictive Biomarker in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Overview of attention for article published in Frontiers in oncology, May 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 15 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 10 publications that cite this research output.

10

The most recent citing publications are shown below. View all 10 publications that cite this research output on Dimensions.

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB

Article in Journal for ImmunoTherapy of Cancer (November 2023)

Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors

Article in Frontiers in Immunology (May 2023)

Unique profile on the progress free survival and overall survival in patients with advanced non-small cell lung cancer in the Qujing area, Southwest China

Article in Frontiers in Immunology (February 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.